# A Study of an Intratumoral Oncolytic Virus in Patients With Advanced Metastatic Solid Tumors

> **NCT03954067** · PHASE1 · COMPLETED · sponsor: **Astellas Pharma Global Development, Inc.** · enrollment: 72 (actual)

## Conditions studied

- Metastatic Cancer
- Solid Tumors
- Advanced Cancer

## Interventions

- **BIOLOGICAL:** ASP9801
- **COMBINATION_PRODUCT:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03954067
- **Lead sponsor:** Astellas Pharma Global Development, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-03
- **Primary completion:** 2024-04-19
- **Final completion:** 2024-04-19
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2025-04-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03954067

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03954067, "A Study of an Intratumoral Oncolytic Virus in Patients With Advanced Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03954067. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*